p53 mutation as a prognostic marker in advanced laryngeal carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 123, Issue 6, 1997, Pages 605-609

  Bradford, Carol R ^a,b,d   Zhu, Shaobo ^a,b   Poore, Judy ^a,b   Fisher, Susan G ^c   Beals, Theodore F ^a,b   Thoraval, Didier ^a   Hanash, Samir M ^a   Carey, Thomas E ^a   Wolf, Gregory T ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d 1901 Taubman ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; PROGNOSIS; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

EID: 0031007650     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1997.01900060047008     Document Type: Article

References (15)

1. Jacobs C, Goffinet DR, Goffinets L, Kohler M, Fee WE. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer: a report from the Northern California Oncology Group. Cancer. 1987; 60:1178-1183.
2. Karp D, Carter R, Vaughn C, et al. Voice preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer: long term follow-up. Proc Am Soc Clin Oncol. 1988; 7:152.
3. Wolf GT, Hong WK, Fisher S, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
4. Toohill RJ, Duncavage JA, Grossman TW, et al. The effects of delay in standard treatment due to induction chemotherapy in two randomized prospective studies. Laryngoscope. 1987;97:407-412.
5. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemia cells that is inhibited by interleukin-6. Nature. 1991;352:345-347.
6. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 1991;82: 1092-1096.
7. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54:2095-2097.
8. Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg. 1995;113:408-412.
9. Sanbrook J, Fritsch EF, Maniatis T. Molecular Cloning. New York, NY: Cold Spring Harbor Laboratory; 1989:2.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
11. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
12. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res. 1992;52:5323-5328.
13. Xu L, Chen YT, Huvos AG, et al. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol. 1994;3:83-92.
14. Arai N, Nomura D, Yokota K, et al. Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol. 1986;6:3232-3239.
15. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation is associated with locoregional recurrence but not decreased survival in head and neck squamous cell carcinoma. J Natl Cancer Inst. In press.